World Psoriasis Day 2019: LEO Pharma launches new cam-paign to reduce the stigma surrounding psoriasis
Ballerup, Denmark, October 24, 2019: LEO Pharma, a global leader in medical dermatology, announced that on October 29, the 15th annual World Psoriasis Day, LEO Pharma is launching a worldwide campaign ‘Change the View’ to minimize stigma for people living with psoriasis.
Increase understanding and reduce stigma related to psoriasis
Psoriasis affects over 125 million people globally – not just physically, but also socially and emotionally.In addition to the visibility of the condition and pain, itching and bleeding caused by psoriasis, many affected people around the world experience social and work-related stigma and discrimination. Stigma, together with physical and psychological comorbidity are the main factors impairing the life of people living with psoriasis – on an acute and a cumulative level.
This means that, for many with psoriasis, everyday interactions such as visiting the hairdresser or going swimming can be a serious challenge. In a study, 94% of psoriasis sufferers said it impacts their social life. It causes embarrassment, lack of self-esteem and increased prevalence of depression. Therefore, the campaign aims to help people better understand psoriasis, and to reduce the negative reactions that are hurtful and debilitating for many people living with the condition.
Inspire new perspectives on stigma
At the heart of the campaign is the belief that psoriasis itself does not cause exclusion – but society’s reaction to it does. The ‘Change the View ‘campaign is built on the hope that this can change.
The campaign includes a series of films, animations, infographics and other relevant content providing new perspectives to the root causes of exclusion and stigma – all under the #ChangeTheView hashtag – as well as a global campaign homepage with more information, details of local organizations and encouragement to get involved.
For more information on the ‘Change the view” campaign and how LEO Pharma is supporting World Psoriasis Day 2019, please visit www.leo-pharma.com/WPD2019/
Contacts
Trine Juul Wengel
Corporate Communications Manager
Global Branding and External Communication
Email: tewdk@leo-pharma.com
Mobile: +45 20732037
Links
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%15.5.2025 09:00:00 CEST | Pressemeddelelse
Three-month interim report (Q1) 2025 (Unaudited)
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership13.5.2025 13:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 13 May 2025 -- At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term and the profiles required to shape our future. In light of this, we are announcing the following changes to our Executive Management team: We will split the current Product Strategy and International Operations into two functions, and with this EVP Becki Morison will be leaving LEO Pharma, effective end of June 2025. Frederik Kier has been appointed as EVP, International Operations and will start at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from a position as Senior Vice President, Global Obesity Unit at Novo Nordisk. Frederik’s long career at Novo Nordisk spans commercial roles, including international experience as SVP Region Northwest Europe, and SVP Region AAMEO (Africa, Asia, Middle East and Oceania). Lisa Elliott, currently Vice President, Gl
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis9.5.2025 12:00:00 CEST | Pressemeddelelse
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis (AD) Temtokibart – also called LEO 138559 – is an investigational IL-22RA1 antagonist
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom